Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study.

ingentiumby ingentium

In Discovery Literature.

Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study.

Publication date: Dec 11, 2025

COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir/ritonavir and molnupiravir in COVID-19 patients with different comorbidities remain unknown. This study aims to compare the effectiveness, including invasive ventilation and mortality, of nirmatrelvir/ritonavir and molnupiravir in the overall population and populations with various comorbidities in Taiwanese patients during the omicron BA. 2 wave. We retrospectively collected electronic medical records from the Taipei Medical University Clinical Research Database between January and December 2022 and conducted an analysis of adult patients diagnosed with SARS-CoV-2 infection. For data management, we performed propensity score matching to minimize the imbalance between two groups; the standardized mean difference > 0. 1 or a p value 

Open Access PDF

Concepts Keywords
Antiviral Comorbidity
Database COVID-19
December Molnupiravir
Nirmatrelvir Nirmatrelvir/ritonavir
Taiwanese Taiwan

Semantics

Type Source Name
drug DRUGBANK Ritonavir
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH Long Covid
disease MESH Infectious Diseases
disease MESH Dis
disease MESH Lam
pathway REACTOME Reproduction
disease MESH included
disease MESH Infection
disease MESH Emergency
disease MESH Park
disease MESH diabetes mellitus
disease MESH severe acute respiratory syndrome
disease MESH headaches
disease MESH fever
pathway KEGG Viral replication
pathway REACTOME Metabolism
disease MESH NHC
drug DRUGBANK Vorinostat
disease MESH ICD
drug DRUGBANK Methionine
disease MESH pulmonary disease
disease MESH liver disease
disease MESH asthma
pathway KEGG Asthma
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH HIV dementia
disease MESH mental illness
disease MESH malignancies
disease MESH death
disease MESH immune diseases
disease MESH myocardial infarction
disease MESH congestive heart failure
disease MESH peripheral vascular disease
disease MESH cerebrovascular disease
disease MESH dementia
disease MESH SMD
drug DRUGBANK Isoxaflutole
disease MESH hypertension
disease MESH overweight
disease MESH alcoholic fatty liver
disease MESH hematological malignancy
disease MESH anosmia
disease MESH rhinitis
disease MESH sinusitis
disease MESH obesity
disease MESH non alcoholic fatty liver disease
disease MESH Cardiovascular Diseases
disease MESH hhs
drug DRUGBANK Fluvoxamine
disease MESH ICH
drug DRUGBANK Carboxyamidotriazole
disease MESH chronic kidney disease
disease MESH Tam
disease MESH kidney disease

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *